Difference between revisions of "FDG-PET Biomarker Ctte"

From QIBA Wiki
Jump to navigation Jump to search
m
 
(89 intermediate revisions by 4 users not shown)
Line 1: Line 1:
 +
{{TOCright}}
 +
 +
:Co-chairs: Nathan C. Hall, MD, PhD; Jeffrey T. Yap, PhD
 +
:RSNA Staff Support: Julie Lisiecki
 +
* [http://tinyurl.com/QIBA-FDG-PET-Roster Roster]
 +
 
== Quantitative FDG-PET Biomarker Committee Mission ==
 
== Quantitative FDG-PET Biomarker Committee Mission ==
  
Line 6: Line 12:
  
  
==Meetings / Call Summaries==
+
==Recent Meetings / Call Summaries==
  
*[[Monthly FDG-PET Call Summaries]]
+
*[[Media:11 05 2021 QIBA FDG-PET BC Update Summary-FINAL.pdf|November 5, 2021]]
 +
*[[Media:10 04 2021 QIBA FDG-PET BC Update Summary-FINAL.pdf|October 4, 2021]]
  
 +
 +
'''''[[FDG-PET Call Summaries Archive]]'''''
  
 
==Nuclear Medicine Combined Biomarker Committee Calls for FDG-PET, Amyloid, SPECT==
 
==Nuclear Medicine Combined Biomarker Committee Calls for FDG-PET, Amyloid, SPECT==
Line 15: Line 24:
 
*[[Combined Nuclear Medicine Biomarker Committee Call Summaries]]
 
*[[Combined Nuclear Medicine Biomarker Committee Call Summaries]]
  
 +
 +
==Profile Development==
 +
'''<font color=green>Technically Confirmed Profile and Supporting Documents:</font>
 +
*[[Media: QIBA_FDG-PET_Profile_v112.doc|Technically Confirmed QIBA FDG-PET Profile: FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy v112]] ''November 14, 2016''
 +
*[[Media: Technically Confirmed Criteria.docx|Technically Confirmed Criteria]] ''November 14, 2016''
 +
*[[Media: Summary.docx| Summary of Changes to the FDG-PET/CT Profile]] ''November 14, 2016''
 +
 +
'''<font color=green>Recent updates from Dr. Kinahan for BC review:</font>
 +
*[[Media: QIBA_FDG-PET_Profile_v111-edits.doc|Updated QIBA FDG-PET Profile: FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy v111]] ''November 10, 2016''
 +
 +
 +
'''<font color=green>Recent updates from Dr. Turkington for BC review:</font>
 +
*[[Media: QIBA_FDG-PET_Profile_v110-edits.doc|Updated QIBA FDG-PET Profile v110 (edits shown), post Oct 7, 2016 call]]
 +
*[[Media: QIBA_FDG-PET_Profile_v110-clean.doc|Updated QIBA FDG-PET Profile v110 (clean version), post Oct 7, 2016 call]]
 +
*[[Media: scanner-checklist-table-v1.docx|QIBA FDG-PET Scanner Checklist, post Oct 7, 2016 call]]
 +
*[[Media: site-checklist-table-v3.docx|QIBA FDG-PET Site Checklist, post Oct 7, 2016 call]]
 +
 +
 +
Public Comment:
 +
 +
:[http://qibawiki.rsna.org/index.php?title=Work_Product_for_Review#QIBA_Profiles_for_Reference <font color=red>Public Comment Version and Feedback Process - FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy</font>]
 +
 +
*[[ARCHIVE]]
  
 
==UPICT Protocol Development==
 
==UPICT Protocol Development==
 +
 +
*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Oncology FDG-PET CT Protocol, v2.5 Dec-2014]]
 +
*[[Media:UPICT Oncologic FDG-PETCTProtocol 5-20-14.pdf|UPICT Oncology FDG-PET CT Protocol 05-20-2014]]
  
 
*[[Media:UPICT Oncologic FDG-PETCTProtocol 6-07-13.pdf|UPICT Oncology FDG-PET CT Protocol 06-07-2013]]
 
*[[Media:UPICT Oncologic FDG-PETCTProtocol 6-07-13.pdf|UPICT Oncology FDG-PET CT Protocol 06-07-2013]]
Line 45: Line 80:
 
[[Documents / Call Summaries]]
 
[[Documents / Call Summaries]]
  
==Profile Development==
 
 
:[[Media:WIKI Copy of QIBA Profile Dissemination List (revised 12-April-2013).pdf|FDG-PET Profile Public Comment Phase - Association Dissemination List]] ''11-April-2013''
 
 
Public Comment:
 
 
:[http://qibawiki.rsna.org/index.php?title=Work_Product_for_Review#QIBA_Profiles_for_Reference <font color=red>Public Comment Version and Feedback Process - FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy</font>]
 
 
:[[Media:QIBA FDG-PET Profile v104 06Nov2013.doc|QIBA Profile: FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy (v1.04) Reviewed Draft (Public Comments Addressed)]] ''06NOV2013''
 
 
:[[Media:QIBA_FDG-PET_Profile_v104_pre02Aug.call.pdf|QIBA Profile: FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy (v1.04) Version for Public Comment]] ''01AUG2013''
 
 
:[[Media:QIBA_Public_Comment_1 04_pre02Aug.call -OPEN.nonDCOMitems.pdf|QIBA Profile: FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy (v1.04) Summary of Open Public Comment Items for Resolution]] ''01AUG2013''
 
 
:[[Media:QIBA FDG-PET Profile v103 rev 09Mar2013-PK wTC-Roster.pdf|QIBA Profile: FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy (v1.03) Version for Public Comment]] ''09MAR2013''
 
 
:[[Media:QIBA FDG-PET Profile v102 rforPublicComment 21Feb2013.pdf|QIBA Profile: FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy (v1.02) Version for Public Comment]] ''21FEB2013''
 
 
:[[Media:QIBA Public Comment FEEDBACK FDG-PET WholeBody v1 03 09Mar2013.pdf|QIBA Profile: FDG-PET Whole Body v1.03 - Public Comment Summary - Updated 09MAR2013]]
 
 
 
 
Drafting:
 
  
*[[Media:QIBA FDG-PET Profile v0.9.5 ep 25OCT2012.doc|QIBA Profile: FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy (v0.9.5)]] ''4NOV2012''
 
 
*[[Media:QIBA FDG-PET Profile v0.9.5 25OCT2012.doc|QIBA Profile: FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy (v0.9.5)]] ''25OCT2012''
 
 
*[[ARCHIVE]]
 
  
 
==Research Papers Analyzing FDG-PET Test-Retest Variability==
 
==Research Papers Analyzing FDG-PET Test-Retest Variability==
Line 97: Line 104:
 
==Working Documents and Reference Materials==
 
==Working Documents and Reference Materials==
  
 +
*[http://www.sciencedirect.com/science/article/pii/S1550413116303606 QIBA collaborative manuscript on quantitative imaging of brown fat with PET/CT -  link to article]
 
*[[Media: QIBA_FDG-PET_Profile_v104_post24Maycall.pdf|Updated QIBA FDG-PET Profile v104, post May 24, 2013 call]]
 
*[[Media: QIBA_FDG-PET_Profile_v104_post24Maycall.pdf|Updated QIBA FDG-PET Profile v104, post May 24, 2013 call]]
 
*[[Media: QIBA_FDG-PET_Public Comment Feedback_v104_post24Maycall.pdf|Updated QIBA FDG-PET Public Comment Feedback v104, post May 24, 2013 call]]
 
*[[Media: QIBA_FDG-PET_Public Comment Feedback_v104_post24Maycall.pdf|Updated QIBA FDG-PET Public Comment Feedback v104, post May 24, 2013 call]]
Line 116: Line 124:
  
 
*[[Media:Boellaard-Aanbevelingen NEDPAS 2007 - EN- 17032009.pdf|NL Standardization Protocol for Quantitative FDG-PET in multi-Center Trials - Dr Ronald Boellaard]]
 
*[[Media:Boellaard-Aanbevelingen NEDPAS 2007 - EN- 17032009.pdf|NL Standardization Protocol for Quantitative FDG-PET in multi-Center Trials - Dr Ronald Boellaard]]
 +
  
 
'''The Netherlands Standardization Protocol for Quantitative FDG-PET in Multi-center Trials (English translation of Version 1)'''
 
'''The Netherlands Standardization Protocol for Quantitative FDG-PET in Multi-center Trials (English translation of Version 1)'''
Line 155: Line 164:
 
*[[Media:Frank-FDG-PET-20090520.ppt|FDG-PET/CT Technical Committee summary 2009.05.20 Richard Frank]]
 
*[[Media:Frank-FDG-PET-20090520.ppt|FDG-PET/CT Technical Committee summary 2009.05.20 Richard Frank]]
  
==Round 1 of QIBA Funded Projects==
+
==QIBA Funded Projects==
 +
 
 +
====Round 1====
  
 
*[[VU University Medical Center, The Netherlands]]
 
*[[VU University Medical Center, The Netherlands]]
Line 163: Line 174:
 
*[[Johns Hopkins University School of Medicine]]
 
*[[Johns Hopkins University School of Medicine]]
  
==Round 2 of QIBA Funded Projects==
+
====Round 2====
 
 
  
 
*[[VU University Medical Center, The Netherlands, Round-2]]
 
*[[VU University Medical Center, The Netherlands, Round-2]]
Line 171: Line 181:
 
*[[Perlman Advisory Group]]
 
*[[Perlman Advisory Group]]
  
 +
====Round 3====
 +
*[[Media:FDG-PET-CT Profile Field Test.pdf | Project (C) FDG-PET-CT Profile Field Test (Duke University)]]
 +
*[[Media:FDG-PET-CT DRO.pdf | Project (E) FDG-PET-CT Digital Reference Object (DRO) Extension (University of Washington)]]
 +
 +
====Round 4====
 +
*[[Media:FDG-PET-CT Profile Multi-Center Field Test.pdf | Project (R) FDG-PET-CT Profile Multi-Center Field Test (Duke University)]]
 +
 +
====Round 5====
 +
*[[Media:Biologic and Reader Repeatability of FDG and CT Volumetric Parameters.pdf | Project (B) Biologic and Reader Repeatability of FDG and CT Volumetric Parameters (ACRIN 6678 & MERCK) (Johns Hopkins University)]]
 +
 +
====Round 6====
 +
*[[Media:SUV Quantification with Point Spread Function PET Reconstruction.pdf | Project (R) SUV Quantification with Point Spread Function PET Reconstruction (Johns Hopkins University)]]
  
 
==Ideas for Profile version 2.0==
 
==Ideas for Profile version 2.0==

Latest revision as of 16:20, 24 January 2022

Co-chairs: Nathan C. Hall, MD, PhD; Jeffrey T. Yap, PhD
RSNA Staff Support: Julie Lisiecki

Quantitative FDG-PET Biomarker Committee Mission

Mission: Foster adoption of pragmatic and cost effective standards for accurate and reproducible longitudinal quantitation of biologic parameters with clinical relevance and known sigma


Recent Meetings / Call Summaries


FDG-PET Call Summaries Archive

Nuclear Medicine Combined Biomarker Committee Calls for FDG-PET, Amyloid, SPECT


Profile Development

Technically Confirmed Profile and Supporting Documents:

Recent updates from Dr. Kinahan for BC review:


Recent updates from Dr. Turkington for BC review:


Public Comment:

Public Comment Version and Feedback Process - FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy

UPICT Protocol Development


FDG-PET Reporting Standards Writing Group

Problem Statement: • Gap between what is reported and what is needed for meta-analysis to determine value of quantitative imaging biomarkers • This is now established in the literature

Group members as of 5/27/2014:

  • Paul Kinahan, PhD (Co-Chair)
  • Paul Marsden, PhD (Co-Chair)
  • Sally F. Barrington, MD
  • Anastasia Chalkidou, MD
  • Dominique Delbeke, MD, PhD
  • Constantine Gatsonis, PhD
  • Otto Hoekstra, MD, PhD
  • Erich Huang, PhD
  • Lisa McShane, PhD
  • Dan Sullivan, MD
  • Richard L. Wahl, MD


Documents / Call Summaries


Research Papers Analyzing FDG-PET Test-Retest Variability

  • Hatt M, Cheze-Le Rest, C, Aboagye EO, et al. Reproducibility of 18F-FDG and 3'-Deoxy-3'-18F-Fluorothymidine PET Tumor Volume Measurements. The Journal of Nuclear Medicine2010; 51(9):1368-1376. [1]
  • Kamibayashi T, Tsuchida T, Demura Y, et al. Reproducibility of Semi-quantitative Parameters in FDG-PET Using Two Different PET Scanners: Influence of Attenuation Correction Method and Examination Interval. Academy of Molecular Imaging 2008; 10:162-166.[2]
  • Krak NC, Boellaard R, Hoekstra OS, et al. Effects of ROI Definition and Reconstruction Method on Quantitative Outcome and Applicability in a Response Monitoring Trial. European Journal of Nuclear Medicine and Molecular Imaging 2005; 32(3):294–301.[3]
  • Minn H, Zasadny KR, Quint LE, Wahl RL. Lung Cancer: Reproducibility of Quantitative Measurements for Evaluating 2-[F-18]-Fluoro-2-deoxy-D-glucose Uptake at PET1. Radiology 1995; 196:167-173.[4]
  • Nahmias C, Wahl LM. Reproducibility of Standardized Uptake Value Measurements Determined by 18F-FDG PET in Malignant Tumors. The Journal of Nuclear Medicine 2008; 49(11):1804-1808. [5]
  • Nakamoto Y, Zasadny KR, Heikki M, Wahl RL. Reproducibility of Common Semi-quantitative Parameters for Evaluating Lung Cancer Glucose Metabolism with Positron Emission Tomography Using 2-Deoxy-2-[18F] Fluoro-D-Glucose. Molecular Imaging and Biology 2002; 4(2):171-178. [6]
  • Velasquez, LM, Boellaard R, Kollia G, et al. Repeatability of 18F-FDG PET in a Multicenter Phase I Study of Patients with Advanced Gastrointestinal Malignancies. The Journal of Nuclear Medicine 2009;50:1646-1654. [7]
  • Weber WA, Ziegler SI, Thodtmann R, et al. Reproducibility of Metabolic Measurements in Malignant Tumors Using FDG PET. The Journal of Nuclear Medicine 1999; 40(11):1771-1777. [8]


Working Documents and Reference Materials


The Netherlands Standardization Protocol for Quantitative FDG-PET in Multi-center Trials (English translation of Version 1)

Please keep the following in mind:

The development of this protocol was started about 2005 and approved more than 1 year ago in The Netherlands (NL). However, with gained insight, changes are scheduled to be incorporated in the next version by 2010. The following changes will be made (consider them being applied already or underway):

  • Use of oral contrast is now excluded but will be allowed in the next version
  • We are currently working on standards for CT as well, including GL for doing CT-QC (in cooperation with the radiologists/radiology societies in NL)
  • There will be an upper limit for dosage
  • We are working on traceable/calibrated and mutually linked sources for both PET and the dose calibrator and these will be used for absolute (rather than cross-) calibration (but in addition to the cross-calibration using FDG).
  • Reconstruction settings given in the protocol are indicative and are likely not applicable for future scanners and software upgrades. Therefore reconstruction parameters should be set such that they provide results that meet the specifications given for the multi-center QC experiments. Same settings should then be applied to patient studies (see also comments under "execptions/special features” and comments made in the paper by Boellaard et al. EJNMMI 2008).
  • Various other minor edits/typos/changes

The protocol is not a step-by-step description of the logistics for doing a PET/CT study. However, it has been set up in a somewhat chronological order and may thus be used to populate (copy-paste) such a step-by-step description. Additional work required ... FDG-PET/CT Technical Committee input is highly appreciated.

Submitted by Ronald Boellaard, PhD

Submitted by Richard L. Wahl, MD and Martin A. Lodge, PhD

Submitted by Eric S. Perlman, MD

Slide Presentations

QIBA Funded Projects

Round 1

Round 2

Round 3

Round 4

Round 5

Round 6

Ideas for Profile version 2.0

A collection area for ideas to include in the next version of the Profile


A PET Physicist here had this feedback, which I think you will appreciate:

I wish there was a way to accentuate the difference between dose and activity. There is an important distinction with proper definitions. Activity is a measure of decay rate, dps, mCi, MBq, whatever units one prefers. Dose is a measure of energy deposits in matter. A complex phenomena measured in rem, Sv, whatever.